BURLINGTON, Mass., Sept. 30, 2015 /PRNewswire/ -- Decision Resources Group finds that the global gynecological device market will grow as a result of growing awareness of less invasive treatment options and adoption of outpatient and office-based procedures, which are cheaper and more accessible to patients. By 2023, the US market for gynecological devices, valued at over $1.3 billion, will be the largest market in the world.

Other key findings from Medtech 360 reports covering the gynecological device market:

  • The availability of less invasive treatment options will drive a change in treatment algorithms and the choice of device for treating gynecological conditions such as abnormal uterine bleeding (AUB) and uterine fibroids. In particular, hormonal intrauterine devices (IUDs) are being considered as a first-line treatment before more invasive options, including endometrial ablation or hysterectomy.
  • Product innovation continues to be a driver of growth in the gynecological device market. Recent product launches include Boston Scientific's Symphion hysteroscopic morcellator with its own built-in fluid management system, a lower-cost hormonal IUD called Liletta, CooperSurgical's Endosee disposable hysteroscope, and a new endometrial ablation system that has a procedure time of only 3-4 minutes named Minerva, launched by the company of the same name.
  •  The gynecological device market will be limited to some extent by litigation cases related to certain device markets, such as pelvic floor reconstruction (PFR) mesh, vaginal slings, and most recently, the transcervical female sterilization device, Essure. Escalating concerns regarding product safety have resulted in market declines in these segments, and a hesitation towards undergoing these procedures will continue to limit the market in the near future.

Comments from Decision Resources Group Senior Analyst Carmen Chan:

  • "The launch of next-generation devices in the GEA and transcervical sterilization device markets will support market values over the forecast period. These devices will alleviate some of the negative pressures on these markets as a result of poor publicity and litigation. For instance, in the GEA device market, third-generation devices by Minerva Surgical and Aegea Medical, both of which are expected to launch sometime between 2016 and 2018, will help buoy market values and ASPs, reversing the early decline in revenues. Furthermore, Bayer HealthCare and AltaScience are expected to launch new transcervical sterilization devices during the forecast period."
  • "The hysteroscopic morcellator market will continue to grow strongly through 2023. Adoption of hysteroscopic morcellators has been particularly strong in the US because both Hologic and Smith & Nephew have been heavily focusing on building a base of users. Adoption of hysteroscopic morcellators will also be boosted by the general trend toward performing more procedures in outpatient and physician office settings rather than in hospitals in the US. Because hysteroscopic morcellation can be performed in these settings, the procedure is attractive to patients and gynecologists alike."

Additional Resources:

Carmen Chan has written a blog on the subject, which can be found here.

For more information on purchasing this report, please email questions@teamdrg.com.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 14 global locations. DRG provides the pharmaceutical, biotech, medical device, financial services and payer industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. DecisionResourcesGroup.com.

Media contact:
SHIFT Communications
Theresa Masnik

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


SOURCE Decision Resources Group

U.S. Gastroenterologists' Familiarity and Experience with Entyvio has Increased Substantially Since Launch with the Majority Reporting Positive Reactions; Cost and Formulary Access are Currently the Top Perceived Disadvantages

View Now